Cargando…

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes

OBJECTIVE: To investigate the clinical efficacy of insulin glargine combined with acarbose in the treatment of elderly patients with diabetes. METHODS: One hundred and forty-four elderly patients with diabetes who received treatment between December 2016 and December 2017 in Binzhou People’s Hospita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jing, Ji, Jinzhi, Liu, Fuyan, Wang, Lingling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572939/ https://www.ncbi.nlm.nih.gov/pubmed/31258562 http://dx.doi.org/10.12669/pjms.35.3.86

Ejemplares similares

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control – a prospective cohort study
por: Li, Jing, et al.
Publicado: (2018)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
por: Liu, Dan, et al.
Publicado: (2021)

Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus
por: Wettergreen, Sara A., et al.
Publicado: (2016)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
por: He, Ke, et al.
Publicado: (2014)

Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus
por: Jin, Hongmei, et al.
Publicado: (2022)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
por: Wu, Honghua, et al.
Publicado: (2017)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
por: Huang, Jie, et al.
Publicado: (2020)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
por: Rosak, Christoph, et al.
Publicado: (2012)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
por: Tang, Xulei, et al.
Publicado: (2012)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

Retracted: Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
por: Kim, Ji-Hyun, et al.
Publicado: (2015)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial
por: Ji, Linong, et al.
Publicado: (2019)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study
por: Lee, Mi Young, et al.
Publicado: (2014)

Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus
por: Uzui, Hiroyasu, et al.
Publicado: (2011)

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues
por: Simon, D.
Publicado: (2009)

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
por: Hilgenfeld, Rolf, et al.
Publicado: (2014)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
por: Sorli, Christopher, et al.
Publicado: (2013)

Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study
por: Li, Feng-fei, et al.
Publicado: (2015)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco
por: Shihabi, Abdul R, et al.
Publicado: (2013)

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
por: Ueno, Hiroaki, et al.
Publicado: (2015)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
por: Secnik Boye, Kristina, et al.
Publicado: (2006)

Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
por: Ioacara, Sorin, et al.
Publicado: (2015)

Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus
por: Ziaee, Amir, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5cssi2oqoi7a0o5jdfede5q69s